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Head Positioning in Acute Stroke
To the Editor: Anderson et al. (June 22 issue)1 
report that head positioning did not influence 
outcome in patients with acute stroke. The lying-
flat position theoretically increases cerebral per-
fusion, which may alleviate acute ischemia through 
the recruitment of collaterals.2 However, in the 
Head Positioning in Acute Stroke Trial (HeadPoST), 
reported by Anderson et al., many patients had 
conditions that presumably were not the result of 
large perfusion defects: specifically, there were 
patients with stroke mimics (4.9%), lacunar stroke 
(30.2%), or intracerebral hemorrhage (8.4%). 
Moreover, the low median scores on the National 
Institutes of Health Stroke Scale in both study 
groups1 suggest that few patients had proximal 
occlusions of the intracranial arteries, which im-
plies that many patients did not require improve-
ment in their collateral cerebrovascular network 
during acute stroke. The absence of large ische-
mic stroke has been proposed as a possible rea-
son for the failure of endovascular therapy to 
show clinical benefit in some recent trials.3,4 
Head positioning therefore might be evaluated in 
a more selective population, such as patients with 
large strokes or large ischemic areas at risk,5 be-
fore we give up on this nonpharmacologic strategy.
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To the Editor: We write to request clarification 
of the consent process used in HeadPoST, in 
which hospital executives provided institutional 
consent to implement an intervention and patients 
provided individual consent only for postinter-
vention data collection and follow-up. Although 
cluster-randomized trials that expose groups to a 
common intervention (e.g., community water 
sanitation) often preclude prospective individual 
consent, the bed-position intervention in Head-
PoST addressed individual patients (which makes 
it an “individual-cluster” trial).1 Time constraints2 
seemingly did not preclude consent: interventions 
were initiated a median of 7 hours after hospital 
arrival and continued for 24 hours. The investiga-
tors describe the study as having “minimal risk,” 
which is generally defined as risk that is similar 
to the risks involved in daily life (and is distinct 
from equipoise).3 But HeadPoST was directed at 
brain perfusion in acute stroke and was designed 
to detect effects on disability at 90 days. A final 
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rationale the authors provided for cluster consent 
is the avoidance of response bias, but this ratio-
nale could conceivably apply to the forgoing of 
consent in any clinical trial. Thus, it remains un-
clear to us that sufficient justification has been 
provided for bypassing the step of obtaining in-
dividual consent from participants.
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To the Editor: In their evaluation of head posi-
tioning after acute stroke, Anderson et al. report-
ed disability outcome and safety to be similar 
whether patients were maintained in a flat posi-
tion or allowed to sit up, with a head elevation of 
30 degrees, during the first 24 hours after stroke. 
The median time from stroke onset to out-of-bed 
activity and rehabilitation was 38 hours in the 
group that was lying flat. In the Efficacy and 
Safety of Very Early Mobilization within 24 Hours 
of Stroke Onset (AVERT) study, usual care includ-
ed mobilization within the first 24 hours after 
stroke for most patients.1 Moreover, shorter and 
more frequent mobilization soon after acute stroke 
has been shown to improve outcomes at 3 months.2 
The effect of restricting out-of-bed activity on 
outcomes for disability after an acute stroke is 
interesting, especially when considered in light 
of the reduced adherence to the practice of main-
taining patients in a flat-lying position as opposed 
to a sitting-up position in the study by Anderson 
et al. (Table S5 in the Supplementary Appendix, 
available with the full text of the article at NEJM 
.org). It would be interesting to examine the effect 
of discontinuation of the flat-lying position soon 
after stroke in an additional strict, per-protocol 
analysis.
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The authors reply: Sibon et al. raise an appro-
priate question in regard to the potential benefits 
of lying flat after stroke in a highly selected 
group of patients — those with a large ischemic 
penumbra resulting from the proximal occlusion 
of a large vessel. We chose a study design that 
would allow for an efficient evaluation of a plau-
sible, modest treatment effect in a large but care-
fully defined and broad group of patients with 
stroke. The lack of statistical heterogeneity across 
several predefined subgroups — including patho-
logic ischemic subtype — provides some reassur-
ance regarding the consistency of a neutral effect 
on outcome. The well-balanced baseline charac-
teristics of the participants indicate that our cen-
tral method of randomization was robust.
We agree with Feldman et al. that informed 
consent remains the appropriate standard for 
the evaluation of interventions with uncertain or 
known benefits and harms. However, opt-out 
consent is increasingly being used for noninter-
ventional registry studies to maximize participa-
tion and thus the external validity of the accu-
mulated “real-world” data.1 We believe that our 
decision to obtain consent by means of the 
cluster-guardian format was necessary, and this 
format was endorsed by the ethics committees at 
114 hospitals in nine countries for several reasons: 
to minimize recruitment and selection bias; to 
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facilitate rapid implementation of the interven-
tion in large numbers of patients by the clinical 
staff at different institutions, all in the chaos of 
emergency departments; and to avoid potential 
responder bias in the outcome assessments of 
patients (or surrogates) who may have thought 
they had received “nonstandard” care. Our deci-
sion to view the matter of head position as involv-
ing “low risk” was based on several consider-
ations: the insufficient amount of level 1 evidence 
specifying the benefits and harms of head posi-
tioning for patients with acute stroke; the fact 
that people change their head position within 
the ranges being tested during routine hospital 
care and in daily life, as they shift from activity 
during the day to rest and sleep at night; and the 
view that patient care would not be compromised 
by either of the interventions.
Finally, Taito and Yamauchi raise an important 
point regarding an unresolved issue that should 
be addressed in another trial — that of the ap-
propriate timing (and intensity) of early mobili-
zation after acute stroke that follows from the 
unexpected results of the AVERT trial.2 Unfortu-
nately, we did not collect data on the specific 
time that patients began to move outside the 
confines of the bed.
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Transplanting HCV-Infected Kidneys into Uninfected Recipients
To the Editor: Goldberg et al. (June 15 issue)1 
report cure of hepatitis C virus (HCV) infection, 
after transplantation of kidneys infected with 
HCV (genotype 1) into HCV-negative recipients, 
with the use of a 12-week course of elbasvir–
grazoprevir. However, data on other types of 
solid-organ transplantation are lacking. Here, we 
report cure of HCV infection after accidental 
transmission of HCV from one organ donor to 
five different recipients (Table 1). The 55-year-old 
female donor did not belong to a group consid-
ered to be at high risk for HCV infection, and 
routine testing for anti-HCV IgG was negative. 
However, retrospective analysis revealed low-
level HCV RNA (genotype 1a) viremia. All the 
transplant recipients were HCV-negative before 
transplantation and had development of HCV 
viremia in the early post-transplantation period. 
A 12-week course of different sofosbuvir-based 
anti-HCV regimens2-4 was used to treat four of 
the patients. The liver-transplant recipient died 
from septic shock early after transplantation, be-
fore treatment could have been initiated. All four 
recipients who received treatment currently have 
stable graft function and cure of HCV infection 
(sustained virologic response at week 12 after 
treatment).
In summary, we contribute further evidence 
that the early initiation of a sofosbuvir-based 
regimen is an efficient and safe treatment op-
tion in the context of different types of solid-
organ transplantation from an HCV-positive donor 
to an HCV-negative recipient.
Fabian Halleck, M.D 
Klemens Budde, M.D. 
Michael Duerr, M.D.
Charité–Universitätsmedizin Berlin 
Berlin, Germany 
fabian . halleck@ charite . de
and Others
A complete list of authors is available with the full text of this 
letter at NEJM.org.
No potential conflict of interest relevant to this letter was re-
ported.
1. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplan-
tation of HCV-infected kidneys into uninfected recipients. N Engl 
J Med 2017; 376: 2394-5.
The New England Journal of Medicine 
Downloaded from nejm.org on September 29, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
